Tsepamo Plus: Expanded Congenital Abnormalities Surveillance with an Emulated Clinical Trial to Evaluate Weight Impact on Birth Outcomes for Newer ART Regimens

Related grants

Same researchers, same institution, same topic, scored first.

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  Tsepamo Next Generation: Optimizing HIV Treatment and Prevention Strategies for Pregnant Women in Botswana

  Roger L Shapiro · $497K · 2025–2030

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  Point-of-Care HIV Testing and Early Dolutegravir Use for Infants

  Roger L Shapiro · $11K · 2025–2026

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana

  Daniel R. Kuritzkes · $1.3M · 2023–2028

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  A Clinical Trial of Three Broadly Neutralizing Antibodies and Analytic Treatment Interruption in Early-Treated Children in Botswana

  Daniel R. Kuritzkes · $890K · 2023–2028

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  Closing Research Gaps in Antiretroviral Treatment for Pregnant Women and Infants Living with HIV

  Roger L Shapiro · $762K · 2021–2026

• NIH · Harvard University D/B/A Harvard School of Public HealthNot yet scored

  Administrative Core

  Roger L Shapiro · $223K · 2021–2026

• NIH · Harvard University D/B/A Harvard School of Public Health48

  Molecular basis of antimalarial drug resistance in Plasmodium vivax

  Manoj T Duraisingh · $96K · 2022–2027

• NIH · Harvard University D/B/A Harvard School of Public Health45

  Methods for Adaptive Randomized Trials in Infectious Disease Research

  Lee Ding · $46K · 2026–2027

• NIH · Harvard University D/B/A Harvard School of Public Health40

  Developmental regulation of apoptosis as a modifiable driver of radiotherapy-induced neurocognitive impairment in pediatric patients

  Kristopher Andrew Sarosiek · $355K · 2020–2027

• NIH · Harvard University D/B/A Harvard School of Public HealthReviewed

  In Utero Exposure to Medications for Cardiometabolic Conditions and Risk of Congenital Malformations

  Jeremy Philip Brown · $119K · 2025–2027

• NIH · Harvard University D/B/A Harvard School of Public HealthReviewed

  An intersectional approach to transgender and/or nonbinary college student mental health: The role of gender identity, race/ethnicity, socioeconomic status, and campus policy

  Even Paglisotti · $20K · 2024–2025

• NIH · Harvard University D/B/A Harvard School of Public HealthReviewed

  Elucidating the biological mechanisms underlying the association between EBV and MS in African Americans

  Alberto Ascherio · $764K · 2024–2029

• NIH · Iowa State UniversityNot yet scored

  Application of an Illumina MiSeq i100 Plus System to Strengthen Food Safety and Public Health Surveillance in the Vet-LIRN Network

  Ganwu Li · $49K · 2025–2026

• NIH · University of California-IrvineNot yet scored

  Mobile Diagnosis of Congenital Genetic Conditions: A Model for Screening and Surveillance in Low-Resource Settings

  Marius George Linguraru · $300K · 2024–2027

• NIH · Duke UniversityNot yet scored

  1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)

  Panagiotis Kougias · $1.9M · 2023–2030

• NIH · Duke UniversityNot yet scored

  2/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)

  Sean M O'Brien · $711K · 2023–2030

• NIH · Duke UniversityNot yet scored

  1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)

  Panagiotis Kougias · $5K · 2023–2030

• NIH · Duke UniversityNot yet scored

  1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)

  Panagiotis Kougias · $5K · 2023–2030